NEW YORK (Reuters Health) – Three years of weekly treatment with a sustained-release formulation of growth hormone is as safe and effective as standard daily growth hormone (GH)…
NEW YORK (Reuters Health) – Patients requiring chronic nonsteroidal anti-inflammatory drug (NSAID) treatment develop fewer gastric or duodenal ulcers if they take ibuprofen with high-dose famotidine in a…
NEW YORK (Reuters Health) – Long-term outcomes are better for patients with three-vessel coronary artery disease when they undergo off-pump coronary artery bypass grafting rather than percutaneous coronary…
NEW YORK (Reuters Health) – Intravaginal progesterone is a valid alternative to intramuscular administration for luteal phase support in women undergoing in vitro fertilization, according to the results…
NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab…
NEW YORK (Reuters Health) – Analysis of the ST segment on the fetal electrocardiogram combined with conventional cardiotocography during intrapartum monitoring reduces the rate of operative vaginal deliveries…
NEW YORK (Reuters Health) – Overall outcomes of drug-eluting coronary stent (DES) implantation are statistically no worse with 6 months of dual antiplatelet therapy than with 12 months,…
NEW YORK (Reuters Health) – Rituximab monotherapy is “a very good option” for severe cryoglobulinemic vasculitis (CV), according to the authors of an Italian study published online December…
NEW YORK (Reuters Health) – Moxifloxacin is as effective as amoxicillin/clavulanic acid in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD) in the outpatient setting, according…
NEW YORK (Reuters Health) – At 5 years, bipolar radiofrequency (RF) endometrial ablation is more effective than hydrothermablation for controlling menorrhagia, according to a Dutch study reported in…
